Skip to main content
Have a personal or library account? Click to login
Global and Regional Trends in Multiple Sclerosis Incidence with Projections to 2030: A Joinpoint Regression Analysis of the GBD Data 2021 by Socio‑Demographic Index and WHO Regions Cover

Global and Regional Trends in Multiple Sclerosis Incidence with Projections to 2030: A Joinpoint Regression Analysis of the GBD Data 2021 by Socio‑Demographic Index and WHO Regions

Open Access
|Sep 2026

References

  1. Filippi M, Bar‑Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43. doi:10.1038/s41572-018-0041-4.
  2. Karussis D. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: A critical review. J Autoimmun. 2014;48–49:134–142. doi:10.1016/j.jaut.2014.01.022.
  3. Omidi A, Zolfaghari A, Mirab SM, et al. Mapping the complexity of multiple sclerosis: A novel perspective on genetic, environmental, and neurobiological insights. Mol Biol Rep. 2025;52(1):484. doi:10.1007/s11033-025-10572-6.
  4. Kapica‑Topczewska K, Kułakowska A, Kochanowicz J, Brola W. Epidemiology of multiple sclerosis: Global trends, regional differences, and clinical implications. Neurol Neurochir Pol. 2025;59(4):375–384. doi:10.5603/pjnns.103955.
  5. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816–1821. doi:10.1177/1352458520970841.
  6. Khan G, Hashim MJ. Epidemiology of multiple sclerosis: Global, regional, national and sub‑national‑level estimates and future projections. J Epidemiol Glob Health. 2025;15(1):21. doi:10.1007/s44197-025-00353-6.
  7. Forouhari A, Taheri G, Salari M, Moosazadeh M, Etemadifar M. Multiple sclerosis epidemiology in Asia and Oceania: A systematic review and meta‑analysis. Mult Scler Relat Disord. 2021;54:103119. doi:10.1016/j.msard.2021.103119.
  8. Jia D, Zhang Y, Yang C. The incidence and prevalence, diagnosis, and treatment of multiple sclerosis in China: A narrative review. Neurol Sci. 2022;43(8):4695–4700. doi:10.1007/s10072-022-06126-4.
  9. Zhang C, Liu W, Wang L, et al. Prevalence and burden of multiple sclerosis in China, 1990–2019: Findings from the Global Burden of Disease Study 2019. Neurology. 2024;102(11):e209351. doi:10.1212/wnl.0000000000209351.
  10. Kingwell E, Marriott JJ, Jetté N, et al. Incidence and prevalence of multiple sclerosis in Europe: A systematic review. BMC Neurol. 2013;13:128. doi:10.1186/1471-2377-13-128.
  11. García López FJ, García‑Merino A, Alcalde‑Cabero E, de Pedro‑Cuesta J. Incidence and prevalence of multiple sclerosis in Spain: A systematic review. Neurologia. 2024;39(8):639–650. doi:10.1016/j.nrleng.2022.02.004.
  12. Bose G, Thebault SDX, Atkins HL, Freedman MS. Does resetting the immune system fix multiple sclerosis? Can J Neurol Sci. 2020;47(1):1–10. doi:10.1017/cjn.2019.294.
  13. Paz‑Zulueta M, Parás‑Bravo P, Cantarero‑Prieto D, Blázquez‑Fernández C, Oterino‑Durán A. A literature review of cost‑of‑illness studies on the economic burden of multiple sclerosis. Mult Scler Relat Disord. 2020;43:102162. doi:10.1016/j.msard.2020.102162.
  14. Ponzio M, Santoni L, Molina M, Tavazzi E, Bergamaschi R. Economic burden of multiple sclerosis in an Italian cohort of patients on disease‑modifying therapy: Analysis of disease cost and its components. J Neurol. 2024;272(1):50. doi:10.1007/s00415-024-12729-y.
  15. Institute for Health Metrics and Evaluation (IHME). GBD Results Tool. University of Washington; 2021. https://ghdx.healthdata.org/gbd-2021.
  16. Maleki Z, Hassanzadeh J, Aryaie M, Ghaem H. Global trend and geographic distribution of thyroid cancer from 1990 to 2021 and its prediction until 2030. Discov Oncol. 2025;16(1):2034. doi:10.1007/s12672-025-03766-8.
  17. Hyndman RJ, Koehler AB. Another look at measures of forecast accuracy. Int J Forecast. 2006;22(4):679–688. doi:10.1016/j.ijforecast.2006.03.001.
  18. Chai T, Draxler RR. Root mean square error (RMSE) or mean absolute error (MAE)?–Arguments against avoiding RMSE in the literature. Geosci Model Dev. 2014;7(3):1247–1250. doi:10.5194/gmd-7-1247-2014.
  19. Pianosi F, Beven K, Freer J, et al. Sensitivity analysis of environmental models: A systematic review with practical workflow. Environ Model Softw. 2016;79:214–232. doi:10.1016/j.envsoft.2016.02.008.
  20. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–351. doi:10.1002/(SICI)1097-0258(20000215)19:3<;335::AID-SIM336>3.0.CO;2-Z.
  21. Clegg LX, Hankey BF, Tiwari R, Feuer EJ, Edwards BK. Estimating average annual per cent change in trend analysis. Stat Med. 2009;28(29):3670–3682. doi:10.1002/sim.3733.
  22. Irimata KE, Bastian BA, Clarke TC, Curtin SC, Badwe R, Rui P. Guidance for selecting model options in the national cancer institute joinpoint regression software. Vital Health Stat 1. 2022;11:1–22.
  23. Liu J, Fan H, Wang H, et al. Systematic study and 30‑year projections of global and multi‑regional burden of multiple sclerosis, 1990–2021. Medicine. 2025;104(44):e45089. doi:10.1097/md.0000000000045089.
  24. Moghaddam VK, Dickerson AS, Bazrafshan E, et al. Socioeconomic determinants of global distribution of multiple sclerosis: An ecological investigation based on Global Burden of Disease data. BMC Neurol. 2021;21(1):145. doi:10.1186/s12883-021-02170-3.
  25. Zhao P, Guan C, Lu J, et al. Global, regional, and national trends and burden of multiple sclerosis in adolescents and young adults: A data analysis from 1990 to 2021 and projections to 2040. Front Immunol. 2025;16:1685316. doi:10.3389/fimmu.2025.1685316.
  26. Lam T, VoPham T, Munger KL, Laden F, Hart JE. Long‑term effects of latitude, ambient temperature, and ultraviolet radiation on the incidence of multiple sclerosis in two cohorts of US women. Environ Epidemiol. 2020;4(4):e0105. doi:10.1097/ee9.0000000000000105.
  27. Simpson S, Wang W, Otahal P, et al. Latitude continues to be significantly associated with the prevalence of multiple sclerosis: An updated meta‑analysis. J Neurol Neurosurg Psychiatry. 2019;90(11):1193–1200. doi:10.1136/jnnp-2018-320189.
  28. Hwang S, Garcia‑Dominguez MA, Fitzgerald KC, Saylor DR. Association of multiple sclerosis prevalence with sociodemographic, health systems, and lifestyle factors on a national and regional level. Neurology. 2022;99(16):e1813–e1823. doi:10.1212/wnl.0000000000200962.
  29. Lane J, Ng HS, Poyser C, Lucas RM, Tremlett H. Multiple sclerosis incidence: A systematic review of change over time by geographical region. Mult Scler Relat Disord. 2022;63:103932. doi:10.1016/j.msard.2022.103932.
  30. Aderinto N, Olatunji G, Kokori E, et al. Prevalence, characteristics, and treatment outcome of multiple sclerosis in Africa: A systematic review. Discov Med. 2025;2(1):93. doi:10.1007/s44337-025-00294-w.
  31. Koh MJ, Saffari SE, Tye JSN, et al. A comparison of multiple sclerosis disease characteristics across three genetically diverse Asian racial groups in Singapore. Sci Rep. 2024;14(1):14690. doi:10.1038/s41598-024-65575-3.
  32. Kearns PKA, Paton M, O’Neill M, et al. Regional variation in the incidence rate and sex ratio of multiple sclerosis in Scotland 2010–2017: Findings from the Scottish Multiple Sclerosis Register. J Neurol. 2019;266(10):2376–2386. doi:10.1007/s00415-019-09413-x.
  33. Kułakowska A, Bartosik‑Psujek H, Hożejowski R, Mitosek‑Szewczyk K, Drozdowski W, Stelmasiak Z. Selected aspects of the epidemiology of multiple sclerosis in Poland ‑ a multicentre pilot study. Neurol Neurochir Pol. 2010;44(5):443–452. doi:10.1016/s0028-3843(14)60134-1.
  34. Pagalilauan AM, Everest E, Rachimi S, et al. The Canadian collaborative project on genetic susceptibility to multiple sclerosis cohort population structure and disease etiology. Front Neurol. 2025;16:1509371. doi:10.3389/fneur.2025.1509371.
  35. Houzen H, Kano T, Kondo K, Takahashi T, Niino M. The prevalence and incidence of multiple sclerosis over the past 20 years in northern Japan. Mult Scler Relat Disord. 2023;73:104696. doi:10.1016/j.msard.2023.104696.
  36. Buxhoeveden S, Swift‑Scanlan T, Goldman MD, Canissario R, Oh U. Exploring sex‑based mechanisms of inflammation and neurodegeneration in multiple sclerosis. Biol Res Nurs. 2026;28(2):283–295. doi:10.1177/10998004251387318.
  37. Coyle PK. Impact of sex on multiple sclerosis therapy. Neurotherapeutics. 2025;22(4):e00620. doi:10.1016/j.neurot.2025.e00620.
  38. Leffler J, Trend S, Gorman S, Hart PH. Sex‑specific environmental impacts on initiation and progression of multiple sclerosis. Front Neurol. 2022;13:835162. doi:10.3389/fneur.2022.835162.
  39. Maunula A, Laakso SM, Viitala M, Soilu‑Hänninen M, Sumelahti ML, Atula S. Incidence and prevalence of multiple sclerosis during eras of evolving diagnostic criteria‑a nationwide population‑based registry study over five decades. Mult Scler J Exp Transl Clin. 2025;11(1):20552173251326173. doi:10.1177/20552173251326173.
  40. Portaccio E, Magyari M, Havrdova EK, et al. Multiple sclerosis: Emerging epidemiological trends and redefining the clinical course. Lancet Reg Health Eur. 2024;44:100977. doi:10.1016/j.lanepe.2024.100977.
  41. de Menezes FTL, Alencar JMD, Lopes AB, et al. The impact of changing diagnostic criteria on disability in a Brazilian multiple sclerosis cohort. Arq Neuropsiquiatr. 2025;83(6):1–9. doi:10.1055/s-0045-1809662.
  42. Agrawal M, Sridhar S, Surendran AK, Bhatt A, Sriwastava S. Diagnostic evolution in multiple sclerosis: A narrative review of the McDonald criteria from 2001 to 2024. Mult Scler Relat Disord. 2025;106756. doi:10.1016/j.msard.2025.106756.
  43. Maunula A, Laakso SM, Viitala M, Soilu‑Hänninen M, Sumelahti ML, Atula S. Incidence and prevalence of multiple sclerosis during eras of evolving diagnostic criteria—a nationwide population‑based registry study over five decades. Mult Scler J Exp Transl Clin. 2025;11(1):20552173251326173. doi:10.1177/20552173251326173.
  44. Ferrand M, Epstein J, Soudant M, et al. Real‑life evaluation of the 2017 McDonald criteria for relapsing–remitting multiple sclerosis after a clinically isolated syndrome confirms a gain in time‑to‑diagnosis. J Neurol. 2024;271(1):125–133. doi:10.1007/s00415-023-11905-w.
  45. Xu C, Zhou T, Huang W. Response to letter regarding: Incidence, mortality, and DALYs of global pharyngeal cancer: Systematic analysis and projections based on global burden of disease study 2021. Ann Med. 2025;57(1):2564294. doi:10.1080/07853890.2025.2564294.
  46. Huang M, Zhaoli M, Xiu L, Qian R. Epidemiological burden assessment of six major immune‑mediated inflammatory diseases based on the Global Burden of Disease Study 2021: Analyses of age‑standardized incidence, prevalence, mortality, and disability‑adjusted life years. J Transl Autoimmun. 2025;11:100330. doi:10.1016/j.jtauto.2025.100330.
  47. Lu X, Borgonovo E. Global sensitivity analysis in epidemiological modeling. Eur J Oper Res. 2023;304(1):9–24. doi:10.1016/j.ejor.2021.11.018.
  48. GBD 2021 Forecasting Collaborators. Burden of disease scenarios for 204 countries and territories, 2022–2050: A forecasting analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2204–2256. doi:10.1016/s0140-6736(24)00932-2.
  49. Gómez‑Figueroa E, Moreno‑Bernardino CJ, De Alba‑Sánchez AM, et al. The burden of multiple sclerosis in Mexico. Neurology. 2025;104(5):e213343. doi:10.1212/wnl.0000000000213343.
DOI: https://doi.org/10.5334/aogh.5438 | Journal eISSN: 2214-9996
Language: English
Page range: 92 - 92
Submitted on: Jul 3, 2026
Accepted on: Aug 11, 2026
Published on: Sep 8, 2026
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services

© 2026 Hamed Delam, Naeimehossadat Asmarian, Haleh Ghaem, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.